Evidence map›Paper›PMID 27617984›Full record

ArticleMolecules (Basel, Switzerland)2016

Boronic Acid Group: A Cumbersome False Negative Case in the Process of Drug Design.

Sotirios Katsamakas, Anastasios G Papadopoulos, Dimitra Hadjipavlou-Litina

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Merging the Versatile Functionalities of Boronic Acid with Peptides.International journal of molecular sciences · 2021
    Review
  3. Benzoxaboroles-Novel Autotaxin Inhibitors.Molecules (Basel, Switzerland) · 2019
    Article
  4. Drug Design and Discovery: Principles and Applications.Molecules (Basel, Switzerland) · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sotirios KatsamakasDepartment of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece. sotikats@pharm.auth.gr.
Anastasios G PapadopoulosLaboratory of Applied Quantum Chemistry, School of Chemistry, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece. anastp@chem.auth.gr.
Dimitra Hadjipavlou-LitinaDepartment of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece. hadjipav@pharm.auth.gr.
Aristotle University of Thessaloniki · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein we present, an exhaustive docking analysis considering the case of autotaxin (ATX). HA155, a small molecule inhibitor of ATX, is co-crystallized. In order to further extract conclusions on the nature of the bond formed between the ligands and the amino acid residues of the active site, density functional theory (DFT) calculations were undertaken. However, docking does not provide reproducible results when screening boronic acid derivatives and their binding orientations to protein drug targets. Based on natural bond orbital (NBO) calculations, the formed bond between Ser/Thr residues is characterized more accurately as a polar covalent bond instead of a simple nonpolar covalent one. The presented results are acceptable and could be used in screening as an active negative filter for boron compounds. The hydroxyl groups of amino acids are bonded with the inhibitor's boron atom, converting its hybridization to sp³.

Indexed as

Drug DesignModels, MolecularBoronic AcidsCrystallography, X-RayEnzyme InhibitorsHumansLysophospholipase DPhosphoric Diester HydrolasesBoronic AcidsEnzyme InhibitorsLysophospholipase DPhosphoric Diester Hydrolasesautotaxinboronic aciddrug designorganoboronvirtual screeningwarhead

Identifiers

PMID27617984
PMCPMC6273881
OpenAlexW2509295998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.